Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5415]

Vemurafenib plus cobimetinib achieves significant progression-free survival in...

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Nivolumab shows signs of superior response rate compared to standard chemo in...

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )

EORTC and the management of clinical trial data

Anastassia Negrouk - European Organisation for Research and Treatment of Cancer...

EORTC and the management of clinical trial data ( Anastassia Negrouk - European Organisation for Research and Treatment of Cancer, Brussels, Belgium and Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Improvements in progression free survival for patients with metastatic head and...

Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )

Financial impact of a cancer diagnosis

Prof Françoise Meunier - Director General of EORTC, Brussels, Belgium

Financial impact of a cancer diagnosis ( Prof Françoise Meunier - Director General of EORTC, Brussels, Belgium )

Combining cobimetinib and vemurafenib improves progression-free survival in...

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Molecular targeting in cancer and the impact on personalised medicine

Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer...

Molecular targeting in cancer and the impact on personalised medicine ( Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria )

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...

Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )

Cediranib and chemo combo improves PFS for metastatic cervical cancer

Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK

Cediranib and chemo combo improves PFS for metastatic cervical cancer ( Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK )

Phase III trial results raise questions about the future of lung cancer...

Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium

Phase III trial results raise questions about the future of lung cancer vaccination ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )

Little benefit for gefitinib-resistant lung cancer when continuing the drug...

Dr Tony Mok - The Chinese University of Hong Kong, Shatin, China

Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemotherapy ( Dr Tony Mok - The Chinese University of Hong Kong, Shatin, China )

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...

Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )

More from ecancer